London-based COMPASS Pathways plc (Nasdaq: CMPS) has secured $285 million in private funding to advance the company toward offering psychedelics as a treatment for mental health conditions.
The company appears to see a clear path toward FDA approval and has convinced several investors of the opportunity. COMPASS Pathways named 11 investment firms and hinted at others participating in the round. The company said that it expects the funds to carry it through late 2025.
“We view this investment as a validation of the potential of psychedelic medicine and the importance of a rigorous and evidence-based approach,” Kabir Nath, CEO of COMPASS Pathways, said in the release.
Read more
COMPASS Pathways Signal Confidence in Psychedelic Research Efforts with $285M in Funding
